A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates

NCT07520760 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

HER 2 Negative Breast Cancer

Interventions

DRUG: Eribulin in Combination with Anlotinib

Sponsor

Sun Yat-sen University